# Efficacy and Safety of Rifaximin With NAC in IBS-D

> **NCT04557215** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** N-acetylcysteine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04557215
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2021-08-31
- **Final completion:** 2022-10-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557215, "Efficacy and Safety of Rifaximin With NAC in IBS-D". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04557215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*